



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## C16 PEG-Ceramide

<b>Cat. No.:</b>	HY-144005
<b>CAS No.:</b>	212116-78-4
<b>Molecular Formula:</b>	$(C_2H_4O)_n C_{39}H_{73}NO_6$
<b>Target:</b>	Autophagy; Liposome
<b>Pathway:</b>	Autophagy; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	C16 PEG-Ceramide is a polyethylene glycolylated ceramide. C16 PEG-Ceramide can be used for lipid carrier to delivery. C16 PEG-Ceramide induces autophagy. C16 PEG-Ceramide can be used for cancer research <sup>[1][2]</sup> .																
<b>In Vitro</b>	<p>C16 PEG-Ceramide (0-118.6 μM, 24 hours) has cytotoxicity and promotes autophagy in N2a cells<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay<sup>[2]</sup>.</p> <table border="1"> <tr> <td>Cell Line:</td> <td>N2a cells</td> </tr> <tr> <td>Concentration:</td> <td>3.7-118.6 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibits N2a cells activity in a dose-dependent.</td> </tr> </table> <p>Western Blot Analysis<sup>[2]</sup>.</p> <table border="1"> <tr> <td>Cell Line:</td> <td>N2a cells</td> </tr> <tr> <td>Concentration:</td> <td>2.5, 5.0, 10 and 20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Increased the LC3-II/LC3-I ratios, reduced the content of WT-Tau and P301L-Tau proteins in the cells.</td> </tr> </table>	Cell Line:	N2a cells	Concentration:	3.7-118.6 μM	Incubation Time:	24 hours	Result:	Inhibits N2a cells activity in a dose-dependent.	Cell Line:	N2a cells	Concentration:	2.5, 5.0, 10 and 20 μM	Incubation Time:	24 hours	Result:	Increased the LC3-II/LC3-I ratios, reduced the content of WT-Tau and P301L-Tau proteins in the cells.
Cell Line:	N2a cells																
Concentration:	3.7-118.6 μM																
Incubation Time:	24 hours																
Result:	Inhibits N2a cells activity in a dose-dependent.																
Cell Line:	N2a cells																
Concentration:	2.5, 5.0, 10 and 20 μM																
Incubation Time:	24 hours																
Result:	Increased the LC3-II/LC3-I ratios, reduced the content of WT-Tau and P301L-Tau proteins in the cells.																

### REFERENCES

[1]. Su X, et, al. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance. *Nanomedicine (Lond)*. 2015;10(13):2033-50.

[2]. Gao J, et, al. PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells. *Int J Nanomedicine*. 2020 Sep 11;15:6779-6789.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA